Tratamiento de la metanfetamina
Grupo de trabajo sobre tratamiento de la adicción a la metanfetamina (DGPNSD) [+]
- The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder. American Society of Addiction Medicine and American Academy of Addiction Psychiatry, 2024
- Provider pocket guide. The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
- Stimulant use disorder. Practice update. Vancouver: British Columbia Centre for Substance Use, 2022.
- Grigg J., Manning V., Arunogiri S., Volpe I., Frei M., Phan V., Rubenis A., Dias S., Petrie M., Sharkey M. & Lubman D. I. (2018). Methamphetamine Treatment Guidelines: Practice Guidelines for Health Professionals (Second Edition). Richmond, Victoria: Turning Point.
- Guía de práctica clínica de los trastornos relacionados con la metanfetamina. Centro Médico para la Calidad en Medicina (ÄZQ). Ministerio de Sanidad de la RFA, Asociación Médica Alemana, Sociedad de Psiquiatría, Psicoterapia y Psicosomática, 2016. La revisión realizada en 2019 por la Canadian Agency for Drugs and Technologies in Health valoró su desarrollo como riguroso.
Algunos artículos de revisión o de novedades terapéuticas [+]
- Bisaga A. Commentary on Ezard et al.: Prescribed psychostimulant medications for methamphetamine use disorder - an urgent path forward. Addiction. Published online April 1, 2025. doi:10.1111/add.70058
- Ezard N, Clifford B, Siefried KJ, et al. Lisdexamfetamine in the treatment of methamphetamine dependence: A randomised, placebo-controlled trial. Addiction. Published online December 19, 2024. doi:10.1111/add.16730
- Minozzi S, Saulle R, Amato L, et al. Psychosocial interventions for stimulant use disorder. Cochrane Database of Systematic Reviews 2024, Issue 2. Art. No.: CD011866. DOI: 10.1002/14651858.CD011866.pub3
- Tang Z, Zhu Z, Xu J. Psychological Effects of Repetitive Transcranial Magnetic Stimulation on Individuals With Methamphetamine Use Disorder: A Systematic Review and Meta-Analysis. Biol Res Nurs. 2023 Jan;25(1):117-128. doi: 10.1177/10998004221122522. Epub 2022 Aug 23. PMID: 35999040
- Hersi M, Corace K, Hamel C, et al. Psychosocial and pharmacologic interventions for problematic methamphetamine use: Findings from a scoping review of the literature. PLoS One . 2023;18(10):e0292745. doi:10.1371/journal.pone.0292745
- Bakouni H, Sharafi H, Bahremand A, et al. Bupropion for treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of placebo-controlled randomized clinical trials. Drug Alcohol Depend . doi:10.1016/j.drugalcdep.2023.111018
- Sharafi H, Bakouni H, McAnulty C, Drouin S, Coronado-Montoya S, Bahremand A, Bach P, Ezard N, Le Foll B, Schütz CG, Siefried KJ, Tardelli VS, Ziegler D, Jutras-Aswad D. Prescription psychostimulants for the treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of randomized placebo-controlled trials. Addiction. 2023 Oct 25. doi: 10.1111/add.16347
- Acheson LA, Ezard N, Lintzeris N, et al. Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: A pilot feasibility and safety trial. Drug Alcohol Depend. 2022 Dec 1;241:109692. doi: 10.1016/j.drugalcdep.2022.109692
- Heikkinen M, Taipale H, Tanskanen A, Mittendorfer-Rutz E, Lähteenvuo M, Tiihonen J. Association of Pharmacological Treatments and Hospitalization and Death in Individuals With Amphetamine Use Disorders in a Swedish Nationwide Cohort of 13 965 Patients. JAMA Psychiatry. Published online November 16, 2022. doi:10.1001/jamapsychiatry.2022.3788
- Acheson LS, Ezard N, Lintzeris N, et al. Trial protocol of an open label pilot study of lisdexamfetamine for the treatment of acute methamphetamine withdrawal. PLoS One. 2022;17(10):e0275371. doi:10.1371/journal.pone.0275371.
- Trivedi MH, Walker R, Ling W, et al. Bupropion and naltrexone in methamphetamine use disorder. N Engl J Med. 2021; 384(2):140-153. doi: 10.1056/NEJMoa2020214.
- Ezard N, Clifford B, Dunlop A, et al. Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study. BMJ Open . 2021;11(5):e044696. Published 2021 May 18. doi:10.1136/bmjopen-2020-044696.
- Tardelli VS, Bisaga A, Arcadepani FB, Gerra G, Levin FR, Fidalgo TM. Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis. Psychopharmacology (Berl). 2020 Aug;237(8):2233-2255. doi: 10.1007/s00213-020-05563-3.
- Siefried KJ, Acheson LS, Lintzeris N, Ezard N. Pharmacological treatment of methamphetamine/ amphetamine dependence: a systematic review. CNS Drugs. 2020; 34(4):337-365. doi: 10.1007/s40263-020-00711-x.
- Farrell M, Martin NK, Stockings E, et al. Responding to global stimulant use: challenges and opportunities. Lancet. 2019; 394(10209):1652-1667. doi:10.1016/S0140-6736(19)32230-5.
- Gouzoulis-Mayfrank E, Härtel-Petri R, Hamdorf W, et al. Methamphetamine-related disorders. Dtsch Arztebl Int. 2017; 114(26):455-461. doi: 10.3238/arztebl.2017.0455.
Propuestas de reducción de daños [+]
- Harm Reduction International. Harm reduction for stimulant use, 2019.
- Tratamiento farmacológicamente asistido de la adicción a la metanfetamina con estimulantes centrales. Recomendaciones de la Sociedad de Enfermedades Adictivas de la Sociedad Médica Checa Juan Evangelista Purkinje, 2020.
- DGPNSD. Dosier metanfetamina, 2022
- NIDA. ¿Qué tratamientos se están estudiando para el consumo de metanfetamina y su adicción?
- Puedes encontrar los centros de tratamiento en Ayuda cerca de ti
